Navigator Medicines Advances with New Leadership and Clinical Data Navigator Medicines, focusing on autoimmune disease therapies, recently appointed Tosh Butt as CEO and Khurem Farooq as chairman. The company showcased early clinical data for its NAV-240 program, a bispecific antibody, at the American Academy of Dermatology meeting. Navigator continues to build momentum with strategic leadership and innovative treatments.3